# Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Source: https://onco.cc/trials/nct07011719/  
OnCo record `nct07011719` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cabozantinib in renal cell carcinoma, run by Arcus Biosciences, Inc., now recruiting.

## Summary

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma is a phase 3 interventional study registered as NCT07011719 by Arcus Biosciences, Inc., with 720 participants planned, started 2025-09-08 and due to reach its primary completion in 2028-04. Interventions recorded: Casdatifan, Cabozantinib, Placebo. Conditions listed: Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07011719
- Phase: 3
- Setting: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Sponsor: Arcus Biosciences, Inc.
- Enrolled: 720

## Sources

- ClinicalTrials.gov NCT07011719: https://clinicaltrials.gov/study/NCT07011719

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Cabozantinib](https://onco.cc/drugs/cabozantinib/)
- companies: [Arcus Biosciences](https://onco.cc/companies/arcus-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07011719.json